In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.
|Videos|January 6, 2016
Kay Verble Discusses a Study to Characterize Long-Term Survivors of GBM
Author(s)Kay Verble
Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).
Advertisement
Kay Verble, from the Sontag Foundation and Brain Tumor Network, discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).
Rick Sontag, one of our
Newsletter
Stay up to date on cancer updates, research and education
SubscribeAdvertisement
Related to this article
In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
The FDA has approved Pixclara, the first FET-PET imaging agent for glioma in the U.S. Here's what it does, how accurate it is and why it matters for anyone waiting on an MRI result.
Advertisement
Advertisement